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Amaç: Dünya genelinde akut viral hepatitin önde gelen 
nedenlerinden olan ve enterik yolla bulaşan hepatit A infeksiyonu, 
gelişmekte olan ülkelerde değişim göstermiştir. Bu çalışmanın 
amacı İstanbul, Türkiye’de farklı yaş gruplarında hepatit A virusu 
(HAV) seroprevalansının güncel durumunu belirlemektir.
Gereçler ve Yöntemler: Ocak 2011 ve Aralık 2013 yılları 
arasında 3,868 hastaya ait serum örneklerinde anti-HAV IgG 
değerleri mikropartikül enzim immunoassey (MPEIA) yöntemi 
(Architect SR i1000 and i2000, Abbott Diagnostics, Germany) ile 
retrospektif olarak değerlendirilmiştir.
Bulgular: Çalışmada, tüm hastalarda total anti-HAV antikor 
prevalansı %64,8 olarak saptanmıştır. Değerlendirilen 3,868 
serumun %54’ü erkek ve %46’sı kadın hastalardan elde edilmiştir. 
Yaşlara göre seropozitiflik oranları; 0-16 yaş arasında %55, 17-30 
yaş arasında %47, 31-45 yaş arasında %73,5 olarak belirlenmiştir. 
0-30 yaş arasında %50 (972/1944) olan seroprevalans oranı; 46 yaş 
üzerindeki grupta %89 oranı ile anlamlı artış ortaya koymaktadır.
Sonuç: Genç yaş grubundaki seropozitiflik oranlarının 
düşük olması, bu grubu HAV infeksiyonu açısından daha riskli 
kılmaktadır. Sonuçlar, çocukların ve seronegatif genç yetişkinlerin 
HAV’e karşı rutin olarak aşılanmasını desteklemektedir.
Anahtar kelimeler: Hepatit A virüs, Seroprevalans, Hepatit A 
aşısı
Introduction
Hepatitis A virus (HAV) is an important and common cause 
of viral hepatitis worldwide with major differences in 
geographical endemicity and clinical characteristics [1-3]. 
It is usually a self-limited disease but can result in fulminant 
hepatitis and death and it is a significant cause of morbidity 
and socioeconomic losses in many parts of the world [2]. 
Transmission of HAV is predominantly by direct person-to-
person contact through the orofecal route where sanitation 
is poor and living conditions are crowded [1,2]. Infections 
occur early in life . Improvements in sanitation and hygiene 
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have resulted in reduction in the rate of childhood exposure 
in some countries [2]. Since, most infections, especially in 
children, are subclinical, we can estimate HAV infection 
prevalence in a population by determination of the anti-
HAV antibodies [4]. The distribution of anti-HAV antibody 
seroprevalence over several age groups can be used as a 
marker of a useful HAV epidemiologic pattern relating 
to viral transmission through a community [5]. Serologic 
studies help to determine the patterns of endemicity which 
have been identified as low, medium and high. HAV is a 
worldwide virus but highly endemic in developing countries 
[1,4]. The seroprevalence of HAV in Turkey varies among 
geographical regions, but most regions have an intermediate 
endemicity [6,7]. HAV infections can be prevented by 
immunization and HAV vaccine may be used for prophylaxis 
[5].
This study determined the age specific seroprevalence of 
HAV in Istanbul,Turkey.
Materials and Methods
Serum samples were collected from patients of a university 
hospital laboratory and 2 diagnostic laboratories located in 
different regions of Istanbul, which is the most crowded city 
of Turkey. Istanbul is a province which is located in North-
West Turkey with 14 million inhabitants most of whom are 
immigrants from all regions of the country with variable 
socioeconomic levels. A total of 3,868 serum samples were 
analysed from, Istanbul, Turkey between January 2011 
and December 2013. Serum samples were tested to detect 
anti-HAV IgG by microparticle enzyme immunoassay 
(MPEIA) method (Architect SR i1000 and i2000, Abbott 
Diagnostics, Germany). Serums were assigned with codes, 
and demographic characteristics available were age, gender, 
district of laboratory and date of sampling. Serum samples 
were collected from subjects aged 1-79 years and were 
stratified into the following age groups; 0-16, 17-30, 31-45 
years and above 46 years of age. In this study patients’ data 
were analyzed anonymously. This study was approved by 
the Institutional Ethics Committee.
Statistical Analyses
Statistical analyses were performed using SPSS for 
Windows version 16. Chi-squared test and Fisher’s exact 
test were used, considering a value of P<0.05 as statistically 
significant. 
Results
Among the serum samples tested, 54% (2,092/3,868) were 
from male patients and 46% (1,776/3,868) were from 
female patients. There was no difference in seroprevalence 
between gender groups (male 66% and female 63%) 
(P>0.05). The overall seroprevalence rate of anti-HAV 
among the study population was 64.8% (Table I). Anti-HAV 
seroprevalence according to the age groups 0-16, 17-30, 31-
45 years and over 46 years old were 55%, 47%, 73.6% and 
89%, respectively. The seroprevalence was relatively low 
in people under 30 years of age, ranging from 47% to 55%. 
An increase in seropositivity with age was observed in the 
older age groups; the seroprevalence increased from 50% 
(972/1,944) in 0 to 30 years old to 89% in patients older 
than 46 years (P<0.05) (Table II).
Table I. HAV seropositivity and gender difference
Gender Positivite (%) Negative (%) Total
Male 1,384 (66.2) 708 (33.8) 2,092 (100)
Female 1,124 (63.3) 652(36.7) 1,776(100)
Total 2,508 (64.8) 1,360 (35.2) 3,868(100)
Table II. Anti-HAV IgG results according to age groups
Age Positivite (%) Negative (%) Total
0-16 392 (55) 317 (45) 709
17-30 580 (47) 655 (53) 1235
31-45 853 (73.6) 305 (26.4) 1158
>46 683 (89) 83 (11) 766
Discussion
The HAV seroprevalence in a total of 3,868 patients aged 
between 1-79 in Istanbul was detected to be 64.8%. Turkey 
has an intermediate level of anti-HAV seroprevalence with 
differences among various geographical regions [7,8]. A 
recent study which was conducted with 1,173 individuals 
(0-91 years old) in five different geographical regions of 
Turkey found the overall prevalence of anti-HAV antibodies 
to be 64.4% [9]. Although, the authors found differences 
among geographical regions in Turkey (high in South-
Eastern and Eastern regions and low in central and Western 
regions), the overall seropositivity is similar to our results 
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in Istanbul, which is located in the North West part but 
includes people from all over the country.
Age-specific prevalence was 55% in children 0-16 
years, 47% in those 17-30 years in our study. One of the 
studies published in 2002, with 4,462 subjects under the 
age of 30 in nine provinces of Turkey identified an overall 
HAV seroprevalence rate of 71.3% [10]. A study including 
450 people aged under 30 conducted in the Eastern part of 
Turkey showed that seroprevalence was 84%. Frequency 
of HAV infection in the Eastern part of the country is high, 
compared to other regions of Turkey [10]. Another study, 
conducted in Istanbul which included 630 individuals 
between the ages of 5 and 24 years showed that the 
seropositivity of HAV in the whole study population was 
40% [12]. A seroprevalence study found that the HAV 
seropositivity in adolescents was 38% in 2008, while the 
rate in the same region had been 75% in 1998 [13]. Another 
study, conducted in the Western part of Turkey, found that 
the total seropositivity was 44.6% among the individuals 
aged under 18 years and emphasised that the seropositivity 
increases significantly among children at school age and 
also increases parallel to age [14]. A more recent study 
conducted in the Western part of Turkey, including 729 
children 1-18 years old showed that HAV seropositivity 
was 29.5% and that anti-HAV vaccination should be 
considered for preschool children because teenagers are at 
risk of infection in this region [15]. Our study shows that 
half of the children and young adults are seronegative for 
HAV and our results support that the prevalence of HAV 
has decreased in recent years.
Anti-HAV seroprevalence in the 31-45 year age group is 
73.5% and for the over 46 years is 89%, in our study. Most 
of the studies in our country conducted in 2000s revealed 
that HAV seropositivity was up to 90% in adulthood. This 
included young adults older than 26 years old [8,13,16]. 
Some of the studies have shown that the overall HAV 
prevalence rates declined during the past two decades from 
almost 90% to 72% in Turkey [6,16]. Our study has also 
shown that the seroprevalence rates declined especially in 
young adults and our results support this changing pattern. 
The changing pattern of HAV infection (from early childhood 
to adulthood) has been observed in many developing 
countries and young adults are at risk of acquiring the 
infection [17]. Improved sanitation and hygienic conditions 
have contributed to this changing pattern in our country.
The age seroprevalence studies from the countries in 
the Middle East region of intermediate endemicity have 
shown that the immunity rate in this region was 77 to 96% 
between the ages of 15-44 years. European countries have 
a low seroprevalence rate. The immunity rate between the 
ages of 15-44 years was 28 to 56% in Western Europe and 
47 to 76% in Eastern Europe [8]. Our results are similar to 
immunity rates in Europe.
Turkey which is one of the countries of intermediate 
endemicity, is located on two continents and one part of 
Istanbul lies in Europe (Western part) and the other part 
lies in Asia. In countries of intermediate endemicity, 
WHO recommends childhood vaccination [7] and in our 
country HAV vaccine has been included in the national 
immunization program since November, 2012. Since, 
routine HAV vaccination started only a few years ago and 
because of the changing pattern of HAV infection in our 
country, children and young adults should be evaluated 
carefully; our results show that almost half of them are 
susceptible to HAV infection People who are seronegative 
for HAV are at risk of infection and vaccination provides 
pre-exposure protection from HAV infection (2,18). Cost-
effective analyses performed in Ireland showed that where 
HAV immunity is 45% or less, vaccination is the strategy 
of choice, and when immunity is greater than 45%, then 
screening followed by vaccination should be performed 
[19]. A further study from multiple geographical regions 
of Turkey can evaluate cost-effectivity in our country.
In conclusion, HAV seropositivity was detected to 
be strongly age dependent and the seroprevalence of 
HAV in our region has decreased in recent years. The 
results of our study indicate that a majority of people 
older than 46 years old are immune to HAV whereas half 
of people aging 0 to 30 years are susceptible. People 
who have never contracted HAV and have not been 
vaccinated against hepatitis A are at risk of infection. 
HAV vaccination provides preexposure protection from 
HAV infection therefore susceptible people, especially 
children and young adults, should be considered to be 
screened and vaccined if necessary.
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